Epithelial-derived interleukin-23 promotes oral mucosal immunopathology
Tae Sung Kim,Tomoko Ikeuchi,Vasileios Ionas Theofilou,Drake Winslow Williams,Teresa Greenwell-Wild,Armond June,Emmanuel E Adade,Lu Li,Loreto Abusleme,Nicolas Dutzan,Yao Yuan,Laurie Brenchley,Nicolas Bouladoux,Yosuke Sakamachi,NIDCD/NIDCR Genomics and Computational Biology Core,Robert J Palmer Jr,Ramiro Iglesias-Bartolome,Giorgio Trinchieri,Stavros Garantziotis,Yasmine Belkaid,Alex M Valm,Patricia I Diaz,Steven M Holland,Niki M Moutsopoulos
DOI: https://doi.org/10.1016/j.immuni.2024.02.020
IF: 32.4
2024-04-09
Immunity
Abstract:At mucosal surfaces, epithelial cells provide a structural barrier and an immune defense system. However, dysregulated epithelial responses can contribute to disease states. Here, we demonstrated that epithelial cell-intrinsic production of interleukin-23 (IL-23) triggers an inflammatory loop in the prevalent oral disease periodontitis. Epithelial IL-23 expression localized to areas proximal to the disease-associated microbiome and was evident in experimental models and patients with common and genetic forms of disease. Mechanistically, flagellated microbial species of the periodontitis microbiome triggered epithelial IL-23 induction in a TLR5 receptor-dependent manner. Therefore, unlike other Th17-driven diseases, non-hematopoietic-cell-derived IL-23 served as an initiator of pathogenic inflammation in periodontitis. Beyond periodontitis, analysis of publicly available datasets revealed the expression of epithelial IL-23 in settings of infection, malignancy, and autoimmunity, suggesting a broader role for epithelial-intrinsic IL-23 in human disease. Collectively, this work highlights an important role for the barrier epithelium in the induction of IL-23-mediated inflammation.